Summit Therapeutics Inc. [SMMT] is -67.53% lower this YTD. Is it still time to buy?

Summit Therapeutics Inc. [NASDAQ: SMMT] loss -0.72% on the last trading session, reaching $1.38 price per share at the time. The company report on March 3, 2023 that Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Successful capital raise provides a present-time cash runway into the second half of 2024.

Company to host Q4 Earnings Call on March 9, 2023 at 9:00am ET.

Summit Therapeutics Inc. represents 148.58 million in outstanding shares, while the company has a total market value of $386.58 million with the latest information. SMMT stock price has been found in the range of $1.25 to $1.44.

If compared to the average trading volume of 8.20M shares, SMMT reached a trading volume of 6680921 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Summit Therapeutics Inc. [SMMT]:

Janney have made an estimate for Summit Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 28, 2018. While these analysts kept the previous recommendation, Janney raised their target price to Buy. The new note on the price target was released on May 02, 2018, representing the official price target for Summit Therapeutics Inc. stock. Previously, the target price had yet another drop from $30 to $27, while Needham kept a Buy rating on SMMT stock.

The Average True Range (ATR) for Summit Therapeutics Inc. is set at 0.36, with the Price to Sales ratio for SMMT stock in the period of the last 12 months amounting to 386.58. The Price to Book ratio for the last quarter was 1.53, with the Price to Cash per share for the same quarter was set at 0.44.

Trading performance analysis for SMMT stock

Summit Therapeutics Inc. [SMMT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -23.33. With this latest performance, SMMT shares dropped by -56.05% in over the last four-week period, additionally plugging by 7.81% over the last 6 months – not to mention a drop of -50.00% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SMMT stock in for the last two-week period is set at 29.84, with the RSI for the last a single of trading hit 23.59, and the three-weeks RSI is set at 35.39 for Summit Therapeutics Inc. [SMMT]. The present Moving Average for the last 50 days of trading for this stock 3.3023, while it was recorded at 1.6160 for the last single week of trading, and 1.7821 for the last 200 days.

Summit Therapeutics Inc. [SMMT]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Summit Therapeutics Inc. [SMMT] shares currently have an operating margin of -8330.93. Summit Therapeutics Inc.’s Net Margin is presently recorded at -6127.56.

Return on Total Capital for SMMT is now -89.97, given the latest momentum, and Return on Invested Capital for the company is -66.53. Return on Equity for this stock declined to -66.74, with Return on Assets sitting at -52.86. When it comes to the capital structure of this company, Summit Therapeutics Inc. [SMMT] has a Total Debt to Total Equity ratio set at 0.59. Additionally, SMMT Total Debt to Total Capital is recorded at 0.58, with Total Debt to Total Assets ending up at 0.45. Long-Term Debt to Equity for the company is recorded at 0.09, with the Long-Term Debt to Total Capital now at 0.09.

Reflecting on the efficiency of the workforce at the company, Summit Therapeutics Inc. [SMMT] managed to generate an average of -$650,580 per employee. Receivables Turnover for the company is 0.10 with a Total Asset Turnover recorded at a value of 0.01.Summit Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.20 and a Current Ratio set at 8.20.

An analysis of insider ownership at Summit Therapeutics Inc. [SMMT]

There are presently around $11 million, or 1.70% of SMMT stock, in the hands of institutional investors. The top three institutional holders of SMMT stocks are: BAKER BROS. ADVISORS LP with ownership of 2,000,000, which is approximately New of the company’s market cap and around 90.80% of the total institutional ownership; VANGUARD GROUP INC, holding 1,443,558 shares of the stock with an approximate value of $1.99 million in SMMT stocks shares; and MARSHALL WACE, LLP, currently with $0.86 million in SMMT stock with ownership of nearly 342.817% of the company’s market capitalization.

43 institutional holders increased their position in Summit Therapeutics Inc. [NASDAQ:SMMT] by around 5,629,426 shares. Additionally, 16 investors decreased positions by around 768,815 shares, while 11 investors held positions by with 1,656,309 shares. The mentioned changes placed institutional holdings at 8,054,550 shares, according to the latest SEC report filing. SMMT stock had 25 new institutional investments in for a total of 3,845,998 shares, while 9 institutional investors sold positions of 545,984 shares during the same period.


Please enter your comment!
Please enter your name here